International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab

References

• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9–14. doi:10.4161/19420862.2015.989042. PMID:25529996
   PubMed Web of Science ®Google Scholar
• Reichert JM. Metrics for antibody therapeutics development. MAbs. 2010;2(6):695–700. doi:10.4161/mabs.2.6.13603. PMID:20930555
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Medicines under evaluation by the Committee for Medical Products for Human Use (CHMP). 2017; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac05805083eb#section1 (Last accessed 13 June 2017).
   Google Scholar
• Udpa N, Million RP. Monoclonal antibody biosimilars. Nat Rev Drug Discov. 2016;15(1):13–14 doi:10.1038/nrd.2015.12. PMID:26678619
   PubMed Web of Science ®Google Scholar
• Patent expiry dates for best-selling biologicals. Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(4):178–9. doi:10.5639/gabij.2015.0404.040
   Google Scholar
• McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405–417. doi:10.1038/clpt.2011.343. PMID:22318617
   PubMed Web of Science ®Google Scholar
• Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–3196. doi:10.1182/blood-2014-06-583617. PMID:25298038
   PubMed Web of Science ®Google Scholar
• Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community. BioDrugs 2017;31(3):175–187. doi:10.1007/s40259-017-0218-5. PMID:28439817
   PubMed Web of Science ®Google Scholar
• Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013:72(3):315–318. doi:10.1136/annrheumdis-2012-202941. PMID:23390018
   PubMed Web of Science ®Google Scholar
• Vezer B, Buzas Z, Sebeszta M, Zrubka Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016:32(5):829–834. doi:10.1185/03007995.2016.1145579. PMID:26808864
   PubMed Web of Science ®Google Scholar
• Grampp G, Ramanan S. The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders. BioDrugs. 2015;29(6):365–372. doi:10.1007/s40259-015-0147-0. PMID:26581551
   PubMed Web of Science ®Google Scholar
• Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs. 2014;28(4):363–372. PMID:24567263
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs. 2013:5(5):621–623. PMID:23924791
   PubMed Web of Science ®Google Scholar
• Nikolov NP, Shapiro MA. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology. Nat Rev Rheumatol 2017;13(2):123–128. PMID:28053335
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). 2012; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf.
   Google Scholar
• US Food and Drug Administration. Guidance to Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. 2015; Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf
   Google Scholar
• World Health Organization, Expert Committee on Biological Standardization. Fixty seventh report. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). 2017; WHO Technical Report series 1004:93-127. Available from: http://apps.who.int/iris/bitstream/10665/255657/1/9789241210133-eng.pdf
   Google Scholar
• World Health Organization, Expert Committee on Biological Standardization. Fixty sixth report. Global needs in standardization of products derived by biotechnology. 2016; WHO Technical Report series. 999:13–15. Available from: http://www.who.int/biologicals/expert_committee/WHO_TRS_999_FINAL.pdf?ua=1
   Google Scholar
• Wadhwa M, Kang HN, Knezevic I, Thorpe R, Griffiths E. WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010. Biologicals. 2011;39(5):349–357.
   PubMed Web of Science ®Google Scholar
• Thorpe R, Wadhwa M. Intended use of reference products & WHO International Standards/Reference Reagents in the development of similar biological products (biosimilars). Biologicals. 2011;39(5):262–265. PMID:21880508
   PubMed Web of Science ®Google Scholar
• World Health Organization, Expert Committee. The 19th WHO Model list of Essential Medicine. 2015; WHO Technical Report series 994:417–470. Available from: http://apps.who.int/iris/bitstream/10665/189763/1/9789241209946_eng.pdf.
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hanel A, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13):4003–4008. PMID:16946304
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–3732. doi:10.1182/blood-2005-01-0016. PMID:16123223
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. MabThera: European Public Assessment report (EPAR)—Scientific Discussion. European Medicines Agency. 2005; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf.
   Google Scholar
• European Medicines Agency. MabThera: European Public Assessment report (EPAR)—Product information. 2016; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf.
   Google Scholar
• Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T. 2010:35(3):148–157. PMID:20442809
   PubMedGoogle Scholar
• Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg. 2009;6(1):13–19. doi:10.1016/j.ddstr.2009.10.001. PMID:20379381
   PubMedGoogle Scholar
• Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. 2009;30(7):356–362. doi:10.1016/j.tips.2009.04.007. PMID:19552968
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823–3837. doi:10.1016/j.molimm.2007.06.151. PMID:17768100
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359–7368. doi:10.1038/sj.onc.1206939. PMID:14576843
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. 2010;116(19):3705–3714. doi:10.1182/blood-2010-04-001230. PMID:20610811
   PubMed Web of Science ®Google Scholar
• World Health Organization, Expert Committee on Biological Standardization. Sixty fifth report. Proposed First WHO reference reagent for Rituximab for use in Complement dependent cytotoxicity assays. 2015; WHO Technical Report Series. 993:36–37. Available from: http://apps.who.int/iris/bitstream/10665/173739/1/9789240694095_eng.pdf
   Google Scholar
• Wadhwa M, Bird C, Dilger P, Rigsby P, Jia H, Gross MEB, participants of the s. Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study. J Immunol Methods. 2017;447:14–22. doi:10.1016/j.jim.2017.03.007. PMID:28288790
   PubMed Web of Science ®Google Scholar
• Hubbard AR. Potency labeling of novel factor VIII and factor IX concentrates: past experience and current strategy. Semin Thromb Hemost. 2015;41(8):849–854. doi:10.1055/s-0034-1395353. PMID:25703515
   PubMed Web of Science ®Google Scholar
• Kirkwood TB. Predicting the stability of biological standards and products. Biometrics. 1977;33(4):736–742. doi:10.2307/2529472. PMID:588659
   PubMed Web of Science ®Google Scholar
• World Health Organization, Expert Committee on Biological Standardization.Fifty fifth report. Recommendations for the preparation, characterization and establishment of international and other biological reference standards. 2006; WHO Technical Report Series. 932:73–130. Available from: http://apps.who.int/iris/bitstream/10665/43278/1/WHO_TRS_932_eng.pdf.
   Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310–312. doi:10.1038/nbt.1839. PMID:21478841
   PubMed Web of Science ®Google Scholar
• Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, Surowy T. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. J Immunol Methods. 2014;414:69–81. doi:10.1016/j.jim.2014.07.010. PMID:25086226
   PubMed Web of Science ®Google Scholar
• Kellner C, Derer S, Valerius T, Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods. 2014:65(1):105–113. doi:10.1016/j.ymeth.2013.06.036. PMID:23851282
   PubMed Web of Science ®Google Scholar
• Kim S, Song J, Park S, Ham S, Paek K, Kang M, Chae Y, Seo H, Kim HC, Flores M. Drifts in ADCC-related quality attributes of Herceptin(R): Impact on development of a trastuzumab biosimilar. MAbs. 2017;9(4):704–714. doi:10.1080/19420862.2017.1305530. PMID:28296619
   PubMed Web of Science ®Google Scholar
• Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res. 2006;12(9):2879–2887. doi:10.1158/1078-0432.CCR-05-2619. PMID:16675584
   PubMed Web of Science ®Google Scholar
• Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol. 2006:43(8):1183–1193. doi:10.1016/j.molimm.2005.07.010. PMID:16102830
   PubMed Web of Science ®Google Scholar
• Chung S, Lin YL, Reed C, Ng C, Cheng ZJ, Malavasi F, Yang J, Quarmby V, Song A. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. J Immunol Methods. 2014;407:63–75 doi:10.1016/j.jim.2014.03.021. PMID:24704820
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007:110(7):2561–2564. doi:10.1182/blood-2007-01-070656. PMID:17475906
   PubMed Web of Science ®Google Scholar
• Hsieh YT, Aggarwal P, Cirelli D, Gu L, Surowy T, Mozier NM. Characterization of FcgammaRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells. J Immunol Methods. 2017;441:56–66. PMID:27939300
   PubMed Web of Science ®Google Scholar
• Mata MM, Mahmood F, Sowell RT, Baum LL. Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays. J Immunol Methods. 2014:406:1–9. doi:10.1016/j.jim.2014.01.017. PMID:24561308
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medical Products for Human Use (CHMP). Assessment report, Remsima. 2013; EMA/CHMP/589317/2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf
   Google Scholar
• Schiestl M, Li J, Abas A, Vallin A, Millband J, Gao K, Joung J, Pluschkell S, Go T, Kang HN. The role of the quality assessment in the determination of overall biosimilarity: a simulated case study exercise. Biologicals. 2014;42(2):128–132. doi:10.1016/j.biologicals.2013.11.009. PMID:24373974
   PubMed Web of Science ®Google Scholar
• Biosimilars of Rituximab. Generics and Biosimilars Initiative Journal (GaBI Online). Mol, Belgium: Pro Pharma Communications International; [cited 2017 Apr 14]. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab.
   Google Scholar
• Schneider CK, Vleminckx C, Gravanis I, Ehmann F, Trouvin JH, Weise M, Thirstrup S. Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol. 2012;30(12):1179–1185. doi:10.1038/nbt.2447. PMID:23222783
   PubMed Web of Science ®Google Scholar
• Bristow AF, Barrowcliffe T, Bangham DR. Standardization of biological medicines: the first hundred years, 1900-2000. Notes Rec R Soc Lond. 2006;60(3):271–289. doi:10.1098/rsnr.2006.0153. PMID:17212227
   PubMed Web of Science ®Google Scholar
• World Health Organization, Expert Committee on Biological Standardization. Sixty sixth report. Report of a WHO informal consultation on international standards for biotherapeutic products. 2016; WHO Technical Report series 999:13–15. Available from: http://apps.who.int/iris/bitstream/10665/208900/1/9789240695634-eng.pdf
   Google Scholar